Thomas J Lynch

US Patent:

6853963, Feb 8, 2005

Filed:

May 25, 1999

Appl. No.:

09/318286

Inventors:

Larry Apfelbaum - West Newton MA, US
Peter L. Savage - Mont Vernon NH, US
Mark Trumpler - Lexington MA, US
John D. Doyle - Hollis NH, US
Thomas Lynch - Hollis NH, US
Ramesh Vaswani - Nashua NH, US

Assignee:

Empirix Inc. - Waltham MA

International Classification:

G06F009/45

US Classification:

703 2, 703 22, 703 17, 717126

Abstract:

A method of using a computer to analyze an extended finite state machine model of a system includes providing a graphical user interface that presents a table of rows, receiving data in at least one table row, and determining at least one path through the states and transitions of the extended finite state machine model using at least one of the rows in the table.

US Patent:

7294468, Nov 13, 2007

Filed:

Dec 5, 2005

Appl. No.:

11/294621

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnson - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6, 424 91, 435 912

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

7716050, May 11, 2010

Filed:

Nov 17, 2003

Appl. No.:

10/716027

Inventors:

Laurence S. Gillick - Newton MA, US
Thomas E. Lynch - Framingham MA, US
Michael J. Newman - Somerville MA, US
Daniel L. Roth - Boston MA, US
Steven A. Wegmann - Cambridge MA, US
Jonathan P. Yamron - Sudbury MA, US

Assignee:

Voice Signal Technologies, Inc. - Woburn MA

International Classification:

G10L 15/00

US Classification:

704254

Abstract:

A method for speech recognition. The method uses a single pronunciation estimator to train acoustic phoneme models and recognize utterances from multiple languages. The method includes accepting text spellings of training words in a plurality of sets of training words, each set corresponding to a different one of a plurality of languages. The method also includes, for each of the sets of training words in the plurality, receiving pronunciations for the training words in the set, the pronunciations being characteristic of native speakers of the language of the set, the pronunciations also being in terms of subword units at least some of which are common to two or more of the languages. The method also includes training a single pronunciation estimator using data comprising the text spellings and the pronunciations of the training words.

US Patent:

7964349, Jun 21, 2011

Filed:

Aug 20, 2007

Appl. No.:

11/894159

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

8065144, Nov 22, 2011

Filed:

Feb 3, 2010

Appl. No.:

12/699172

Inventors:

Laurence S. Gillick - Newton MA, US
Thomas E. Lynch - Framingham MA, US
Michael J. Newman - Somerville MA, US
Daniel L. Roth - Boston MA, US
Steven A. Wegmann - Cambridge MA, US
Jonathan P. Yamron - Sudbury MA, US

Assignee:

Voice Signal Technologies, Inc. - Woburn MA

International Classification:

G10L 15/06
G10L 15/28

US Classification:

704243, 704255

Abstract:

A method for speech recognition. The method uses a single pronunciation estimator to train acoustic phoneme models and recognize utterances from multiple languages. The method includes accepting text spellings of training words in a plurality of sets of training words, each set corresponding to a different one of a plurality of languages. The method also includes, for each of the sets of training words in the plurality, receiving pronunciations for the training words in the set, the pronunciations being characteristic of native speakers of the language of the set, the pronunciations also being in terms of subword units at least some of which are common to two or more of the languages. The method also includes training a single pronunciation estimator using data comprising the text spellings and the pronunciations of the training words.

US Patent:

8105769, Jan 31, 2012

Filed:

Aug 20, 2007

Appl. No.:

11/894135

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

8465916, Jun 18, 2013

Filed:

Aug 20, 2007

Appl. No.:

11/894160

Inventors:

Daphne Winifred Bell - Arlington MA, US
Daniel A. Haber - Chestnut Hill MA, US
Pasi Antero Janne - Newton MA, US
Bruce E. Johnston - Brookline MA, US
Thomas J. Lynch - Newton MA, US
Matthew Meyerson - Concord MA, US
Juan Guillermo Paez - Boston MA, US
William R. Sellers - Chestnut Hill MA, US
Jeffrey E. Settleman - Newton MA, US
Raffaella Sordella - Bedford MA, US

Assignee:

The General Hospital Corporation - Boston MA
Dana Farber Cancer Institute, Inc. - Boston MA

International Classification:

C12Q 1/68

US Classification:

435 61

Abstract:

The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

US Patent:

20020133588, Sep 19, 2002

Filed:

Mar 19, 2002

Appl. No.:

10/100883

Inventors:

John Doyle - Hollis NH, US
Thomas Lynch - Hollis NH, US
Neelesh Agrawal - Wakefield MA, US
Kevin Davis - North Reading MA, US

International Classification:

G06F015/173

US Classification:

709/224000

Abstract:

A multi-protocol communication analysis system can analyze and report on the progress of the transport of a communication across a network having a plurality of protocol conversions. A user of the multi-protocol communication analysis system can view the transport analysis.

Author:

Thomas Lynch

ISBN #:

0140276238

Author:

Thomas Lynch

ISBN #:

0199206805

Author:

Thomas Lynch

ISBN #:

0224039733

Author:

Thomas Lynch

ISBN #:

0393041123

Author:

Thomas Lynch

ISBN #:

0393042065

Author:

Thomas Lynch

ISBN #:

0393046591

Author:

Thomas Lynch

ISBN #:

0393049272

Author:

Thomas Lynch

ISBN #:

0393319733